Characteristics, blood counts, treatments, and clinical outcomes of 5871 patients with polycythemia vera treated in US community practices
Nearly half of high-risk patients with PV did not receive pharmacologic cytoreductive treatment. Of those who did, over half had suboptimal response, suggesting these patients may need dose adjustments, improved adverse effect management, or alternative treatments. Longer follow-up may be needed to assess an association between HU response and survival.
Authors
- Kathleen M. Aguilar (ORCID: https://orcid.org/0000-0002-2467-8663)
- Roger M. Lyons (ORCID: https://orcid.org/0000-0001-6508-8080)
- Ira Zackon (ORCID: https://orcid.org/0009-0005-8495-0277)
- Divea Venkatasetty
- Lavanya Sudharshan
- Juliet Ndukum
- Jingbo Yu (ORCID: https://orcid.org/0000-0001-9819-0735)
Institutions
- The US Oncology Network (US)
- Incyte (United States) (US)
Publication Details
- Journal
- Current Medical Research and Opinion
- Published
- 2024-12-20
- DOI
- https://doi.org/10.1080/03007995.2024.2438996
- Citations
- 3
- Primary Topic
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.31
Funders
- Incyte